Updated on 9 April 2013
India is leveraging on MNCs’ need to collaborate
Charles Darwin had pointed out that "In the long history of humankind (and animal kind, too) those who learned to collaborate and improvise most effectively have prevailed". The same is now true for the several industries, which have performed marvelously when they have collaborated with other firms. One of the most successful examples of collaboration is that of Apple. Apple redefined the mobile music sector by outsourcing the production of devices and accessories while retaining control of the iTunes software. The company, in the beginning itself, recognized that it could make money by creating and orchestrating a network of relationships.
Even in the bioscience sector, gone are those days, when a research was kept very secret and not discussed with the competitors. For instance, big pharma, whose traditional business model relied on the ability to identify promising molecules, test them in clinical trials, and promote them with an exclusive marketing and sales presence, has changed its ‘profit alone' model and evolved into ‘profit together' model. PriceWaterhouseCoopers predicts that by 2020, no pharmaceutical company will be able to ‘profit alone' and will have to profit together by joining forces with a wide range of organizations. Several business models have now evolved allow effective collaborations with companies.
India riding fast on collaborations
In 2012, Indian companies were swiftly changing gears to expand to different regions of the world through various collaborations. Be it a generic pharmaceutical company such as Ranbaxy or a vaccine firm such as Bharat Biotech, Indian companies felt the need to make their presence felt in other parts of the world and they decided to explore various partnership models for this purpose.
Bharat Biotech, an integrated biotech company, which is famous for developing $1 rotavirus vaccine, established several partnerships during the past few years to advance basic science research and product development of vaccines against neglected diseases. The company is in the process of developing a novel rotavirus vaccine in partnership with the Center for Disease Control, US; National Institute of Health, US; Stanford University, US; Program for Appropriate Technologies in Health (PATH); AIIMS, New Delhi; IISC, Bangalore; THSTT, New Delhi and Department of Biotechnology, India. The phase III trial is now being conducted of this vaccine which will cost $1 by the Society for Applied Studies, KEM Pune, and CMC Vellore, in India.
To develop a novel vaccine against Japanese encephalitis disease, Bharat Biotech had partnered with the National Institute of Virology, Pune. This partnership has resulted in the completion of phase III clinical trials for a novel thermo stable Japanese Encephalitis vaccine. This vaccine chromatographically purified inactivated vaccine, is safe and highly efficacious based on existing clinical trial data and offers extended protection. Bharat Biotech has demonstrated by collaborating with several institutes that collaboration to bring out cheaper vaccine in a short period of time is possible through collaborations.